357 related articles for article (PubMed ID: 32326356)
1. Sequential Interferon β-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent Manner.
Yang PM; Hsieh YY; Du JL; Yen SC; Hung CF
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326356
[TBL] [Abstract][Full Text] [Related]
2. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress.
Martins I; Kepp O; Schlemmer F; Adjemian S; Tailler M; Shen S; Michaud M; Menger L; Gdoura A; Tajeddine N; Tesniere A; Zitvogel L; Kroemer G
Oncogene; 2011 Mar; 30(10):1147-58. PubMed ID: 21151176
[TBL] [Abstract][Full Text] [Related]
3. Quantification of eIF2alpha phosphorylation during immunogenic cell death.
Bezu L; Wu Chuang A; Humeau J; Kroemer G; Kepp O
Methods Enzymol; 2019; 629():53-69. PubMed ID: 31727256
[TBL] [Abstract][Full Text] [Related]
4. The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells.
Colangelo T; Polcaro G; Ziccardi P; Muccillo L; Galgani M; Pucci B; Milone MR; Budillon A; Santopaolo M; Mazzoccoli G; Matarese G; Sabatino L; Colantuoni V
Cell Death Dis; 2016 Feb; 7(2):e2108. PubMed ID: 26913599
[TBL] [Abstract][Full Text] [Related]
5. STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cells.
Jafari S; Lavasanifar A; Hejazi MS; Maleki-Dizaji N; Mesgari M; Molavi O
Daru; 2020 Jun; 28(1):159-169. PubMed ID: 31942696
[TBL] [Abstract][Full Text] [Related]
6. Consensus guidelines for the detection of immunogenic cell death.
Kepp O; Senovilla L; Vitale I; Vacchelli E; Adjemian S; Agostinis P; Apetoh L; Aranda F; Barnaba V; Bloy N; Bracci L; Breckpot K; Brough D; Buqué A; Castro MG; Cirone M; Colombo MI; Cremer I; Demaria S; Dini L; Eliopoulos AG; Faggioni A; Formenti SC; Fučíková J; Gabriele L; Gaipl US; Galon J; Garg A; Ghiringhelli F; Giese NA; Guo ZS; Hemminki A; Herrmann M; Hodge JW; Holdenrieder S; Honeychurch J; Hu HM; Huang X; Illidge TM; Kono K; Korbelik M; Krysko DV; Loi S; Lowenstein PR; Lugli E; Ma Y; Madeo F; Manfredi AA; Martins I; Mavilio D; Menger L; Merendino N; Michaud M; Mignot G; Mossman KL; Multhoff G; Oehler R; Palombo F; Panaretakis T; Pol J; Proietti E; Ricci JE; Riganti C; Rovere-Querini P; Rubartelli A; Sistigu A; Smyth MJ; Sonnemann J; Spisek R; Stagg J; Sukkurwala AQ; Tartour E; Thorburn A; Thorne SH; Vandenabeele P; Velotti F; Workenhe ST; Yang H; Zong WX; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014 Oct; 3(9):e955691. PubMed ID: 25941621
[TBL] [Abstract][Full Text] [Related]
7. Chromomycin A
Florêncio KGD; Edson EA; Fernandes KSDS; Luiz JPM; Pinto FDCL; Pessoa ODL; Cunha FQ; Machado-Neto JA; Wilke DV
Front Immunol; 2022; 13():941757. PubMed ID: 36439184
[TBL] [Abstract][Full Text] [Related]
8. eIF2α phosphorylation is pathognomonic for immunogenic cell death.
Bezu L; Sauvat A; Humeau J; Gomes-da-Silva LC; Iribarren K; Forveille S; Garcia P; Zhao L; Liu P; Zitvogel L; Senovilla L; Kepp O; Kroemer G
Cell Death Differ; 2018 Aug; 25(8):1375-1393. PubMed ID: 29358668
[TBL] [Abstract][Full Text] [Related]
9. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway.
Zitvogel L; Kepp O; Senovilla L; Menger L; Chaput N; Kroemer G
Clin Cancer Res; 2010 Jun; 16(12):3100-4. PubMed ID: 20421432
[TBL] [Abstract][Full Text] [Related]
10. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments.
Inoue H; Tani K
Cell Death Differ; 2014 Jan; 21(1):39-49. PubMed ID: 23832118
[TBL] [Abstract][Full Text] [Related]
11. Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death.
Kopecka J; Godel M; Dei S; Giampietro R; Belisario DC; Akman M; Contino M; Teodori E; Riganti C
Cells; 2020 Apr; 9(4):. PubMed ID: 32331368
[TBL] [Abstract][Full Text] [Related]
12. Late-stage inhibition of autophagy enhances calreticulin surface exposure.
Li DD; Xie B; Wu XJ; Li JJ; Ding Y; Wen XZ; Zhang X; Zhu SG; Liu W; Zhang XS; Peng RQ
Oncotarget; 2016 Dec; 7(49):80842-80854. PubMed ID: 27825129
[TBL] [Abstract][Full Text] [Related]
13. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.
Garg AD; More S; Rufo N; Mece O; Sassano ML; Agostinis P; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2017; 6(12):e1386829. PubMed ID: 29209573
[TBL] [Abstract][Full Text] [Related]
14. eIF2α phosphorylation as a biomarker of immunogenic cell death.
Kepp O; Semeraro M; Bravo-San Pedro JM; Bloy N; Buqué A; Huang X; Zhou H; Senovilla L; Kroemer G; Galluzzi L
Semin Cancer Biol; 2015 Aug; 33():86-92. PubMed ID: 25749194
[TBL] [Abstract][Full Text] [Related]
15. Targeting immunogenic cell death in cancer.
Ahmed A; Tait SWG
Mol Oncol; 2020 Dec; 14(12):2994-3006. PubMed ID: 33179413
[TBL] [Abstract][Full Text] [Related]
16. Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Solari JIG; Filippi-Chiela E; Pilar ES; Nunes V; Gonzalez EA; Figueiró F; Andrade CF; Klamt F
BMC Cancer; 2020 May; 20(1):474. PubMed ID: 32456685
[TBL] [Abstract][Full Text] [Related]
17. Calreticulin-Multifunctional Chaperone in Immunogenic Cell Death: Potential Significance as a Prognostic Biomarker in Ovarian Cancer Patients.
Kielbik M; Szulc-Kielbik I; Klink M
Cells; 2021 Jan; 10(1):. PubMed ID: 33440842
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies.
Wang Q; Ju X; Wang J; Fan Y; Ren M; Zhang H
Cancer Lett; 2018 Dec; 438():17-23. PubMed ID: 30217563
[TBL] [Abstract][Full Text] [Related]
19. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death.
Garg AD; Dudek AM; Ferreira GB; Verfaillie T; Vandenabeele P; Krysko DV; Mathieu C; Agostinis P
Autophagy; 2013 Sep; 9(9):1292-307. PubMed ID: 23800749
[TBL] [Abstract][Full Text] [Related]
20. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.
Pol J; Vacchelli E; Aranda F; Castoldi F; Eggermont A; Cremer I; Sautès-Fridman C; Fucikova J; Galon J; Spisek R; Tartour E; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2015 Apr; 4(4):e1008866. PubMed ID: 26137404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
